A new generation of cancer immunotherapies

Inovio’s novel DNA immunotherapy technology has created the potential for a new generation of immuno-oncology therapeutics. We are able to design immunotherapies that target multiple antigens of the disease, with techniques designed to break the body’s tolerance against cancerous cells.

We have developed SynCon® immunotherapies to treat a variety of cancers, including HPV-caused pre-cancers and cancers, prostate cancer, and multiple cancers that express the antigen hTERT, including breast, lung, and pancreatic cancer.